However, approved CGM systems demonstrate suboptimal accuracy. Recent meta-analyses have revealed that CGM system-based blood glucose monitoring is more effective for glycemic control in patients of type 1 and 2 DM than self-monitoring of blood glucose. CGM enables the recording of various glucose data, including glucose excursions, patterns, and trends, and timepoints of the associated changes, in an attempt to optimize glycemic control. The current accessibility of continuous glucose monitoring (CGM) systems is considered a valuable development in the management of DM. Glucose monitoring is a crucial aspect of DM control. Furthermore, the optimal strategy for monitoring HbA1c values in patients with DM is not well established. Severe hypoglycemia may be a critical cause of morbidity. However, intensive treatment of DM is accompanied by hypoglycemia. The International Diabetes Federation and American Diabetes Association have reported that the HbA1c value < 7.0% is a target for improving DM control. Accordingly, HbA1c values were hypothesized to represent relatively long-term glycemic status in patients with DM. A study reported a strong correlation between HbA1c values and mean blood glucose levels by using the 7-point blood glucose profiles. HbA1c values are associated with blood glucose levels over the lifetime of red blood cells (approximately 120 days) and are the current gold standard for clinical monitoring of glycemic control in DM. Strict glycemic treatment plays a crucial role in preventing the development and progression of long-term complications associated with DM. ConclusionsĬGM can predict HbA1c values within 1 month after CGM in patients with DM.Ĭlinical investigations have illustrated the correlation of hemoglobin A1c (HbA1c) values with both microvascular and macrovascular complications in patients with diabetes mellitus (DM). The nocturnal blood glucose levels were significantly correlated with HbA1c values 1–3 months before and 1–2 months after CGM. Diurnal blood glucose levels were significantly correlated with HbA1c values 1–2 months before and 1 month after CGM. MAGE and %CV were strongly correlated with HbA1c values 1 and 2 months after CGM, respectively. However, glucose levels recorded in CGM did not correlate with the HbA1c values 3 months after and 2–3 months before CGM. The CGM results were significantly correlated with HbA1c values measured 1 (r = 0.69) and 2 (r = 0.39) months after CGM and 1 month (r = 0.35) before CGM. Diurnal and nocturnal glucose, highest CGM data (10%, 25%, and 50%), mean amplitude of glycemic excursions (MAGE), percent coefficient of variation (%CV), and continuous overlapping net glycemic action were compared with HbA1c values before and after CGM. Data of patients with DM (n = 91) who received CGM and HbA1c testing (1–3 months before and after CGM) were retrospectively analyzed. This study investigated the relationship between HbA1c and CGM, which remained unclear hitherto. Hemoglobin A1c (HbA1c) is a vital outcome predictor in patients with DM. Continuous glucose monitoring (CGM) measures whole-day glucose levels. Glucose monitoring is vital for glycemic control in patients with diabetes mellitus (DM).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |